Theravance Biopharma, Inc.
TBPH
$9.75
$0.212.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -22.28% | 23.18% | -41.71% | -37.06% | 4.92% |
| Total Depreciation and Amortization | -5.33% | -18.51% | 62.17% | -35.22% | 35.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -111.72% | -16.30% | 40.51% | -42.22% | 42.97% |
| Change in Net Operating Assets | 4,160.53% | -112.70% | -34.63% | 220.62% | -153.83% |
| Cash from Operations | 82.64% | -17.69% | -332.00% | -19.67% | 65.65% |
| Capital Expenditure | -1,166.67% | 58.33% | 60.44% | 86.56% | -3,123.81% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 191.33% | -480.43% | -117.50% | -- | -- |
| Cash from Investing | 190.15% | -474.03% | -117.80% | 2,615.21% | -3,123.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 552.00% | -94.03% | -- | -- | -- |
| Repurchase of Common Stock | -33.00% | 14.25% | 73.02% | 94.43% | 1.98% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.88% | -745.45% | 97.44% | 94.39% | 2.53% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 162.78% | -206.64% | -152.41% | 144.46% | 5.22% |